Accession Number:



Inflammation Modulatory Protein TSG-6 for Chemical Injuries to the Cornea

Descriptive Note:

Technical Report,30 Sep 2016,29 Sep 2017

Corporate Author:

Central Texas Veterans Research Foundation Temple United States

Personal Author(s):

Report Date:


Pagination or Media Count:



This period we tested the efficacy of intravenous IV TSG-6 alone, and in combination with topical application. We performed further experiments with anterior chamber AC TSG-6 and high dose IV application, and reported our results at the American Society of Cataract and Refractive Surgery Symposium in Los Angeles in May 2017. We found that IV and AC application reduced selected inflammatory markers at day 1, but not at later time points to day 7, and with no reduction in corneal opacity at any time point. High dose IV TSG-6 or IV TSG-6 in combination with topical TSG-6 did not result in biochemical or clinical benefit, and delayed application of TSG-6 four hours after injury was ineffective. Current experiments are investigating the use of exosomes that contain TSG-6 to determine efficacy in the treatment of corneal alkali burns, and we have submitted an amendment pending approval to investigate the use of TSG-6 containing exosomes in the treatment of nitrogen mustard injury to the eye.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement: